23 rd and 24th September 2013 | duSSeldorf | Germany

business development Conference

Pharma and European Biotech –A valuable Collaboration to Improve Health

European Partners:

Special Partners:

Vereniging Biotechnologische Farmaceutische Industrie

European Association of Pharma Biotechnology EAPB

Second Announcement

»Science to Market«A Discussion and Partnering Conference for Experts from Academia, Biotechnology and Pharmaceutical Industry

October 6 – 7, 2009 | Convention Center, Hannover | Germany

Organised by the European Association of Pharma Biotechnology – EAPB in cooperation with BIOTECHNICA

CMYK

Blue: 100/15/0/35Orange: 0/75/90/0

www.biodeutschland.org/ registration-311.html

The European Association of Pharma Biotechnology (EAPB), the European Biopharmaceutical Enterprises (EBE), Euro-pean Confederation of Pharmaceutical Entrepreneurs (EUCOPE), EuropaBio and BIO Deutschland are pleased to invite you to their joint European business development conference, Pharma meets Biotech – A valuable Collabora-tion to Improve Health, to be held in Dusseldorf (Germany) on 23–24 September 2013.

This year, the conference will be supported – amongst others – by the Spanish Association of Biotechnology Companies (ASEBIO), the UK BioIndustry Association (BIA), the Belgian Association for Bioindustries (Bio.be), the Dutch Pharmacy and Biotechnology Industry Association (BioFarmind), the Industrial Biotechnology Association of Canada (BIOTECanada), the Life Science in Austria (LISA), the Nether lands Biotech Industry Association (Niaba), the Norwegian Bioindustry Association (Norsk Biotekforum), the Swedish Biotech Association (SwedenBIO) and the Swiss Biotech Association (SBA).

The conference aims to bring together a selected group of 100 business development executives from international phar-maceutical corporations and European biotech companies, with representatives from private equity and venture capital companies.

The two-day conference programme offers various oppor-tunities for business networking, company presentations and panel discussions with decision makers from the pharma, biotech and investment sectors. We encourage you to take advantage of the opportunity to become a preferred partner in the joint effort to develop, improve and strengthen innova-tions for tomorrow’s health care sector.

You should also make use of the unique opportunity to present your company: There will be 15-minutes slots for a presentation and Q&A. Further discussions and networking will be possible during coffee breaks, lunch or dinner.

Use the opportunity to become a sponsor! Please contact us at: +49 30 72625-131 (Anette Roll).

The venue Opened in October 2009, the 4 Star Superior Hotel MELIÃ DUSSELDORF is located in the centre of the state capital Dusseldorf, right next to the ‘Green Heart’ and Germany’s oldest public park, the ‘Hofgarten’. The world famous fashion mile ‘Königsallee’ (KÖ) with its exclusive shopping galleries and the historical city centre are within walking distance. The MELIÃ DUSSELDORF distinguishes itself through its modern design and comfortable interior in a very quiet but central location.

For further details please visit: www.biodeutschland.org/business- development-conference-2013.html

We look forward to welcoming you at the Hotel MELIÃ in Dusseldorf!

The ConferenCe

ImpressIons 2010, 2011 and 2012

© B

IO D

euts

chla

nd

AstraZenecaBayerBoehringer Ingelheim Bristol Myers SquibbEdmond de Rothschild

Investment Partners

GalapagosGenzymeHS Life SciencesImmatics BiotechnologiesMerck SeronoMIG

MorphoSysNovartisPfizerRocheSanofiShire

Sinfonie Life Science Management

UCBWellington Partners

With the expected participation of representatives from:

daY one:Monday, 23rd September 2013

daY TWo:Tuesday, 24th September 2013

10.30 – 11.00 Registration / Breakfast

11.00 – 11.15 Opening remarks

11.15 – 11.45 Keynote: How to create sustainable success in the healthcare sector

11.45 – 12.45 Company Presentations

12.45 – 13.45 Lunch

13.45 – 14.45 Company Presentations

14.45 – 16.00 Session I: What is the impact of new tech-nologies and novel therapeutic approaches to fight cancer?

Currently, there are no therapies available that guarantee success and the complete recovery of a cancer patient. New drugs conquer the market that are more efficient than their pred-ecessors and have new mechanisms of action. How is the fight against cancer currently changing? What are the new approaches and how promising are they?

16.00 – 16.45 Coffee Break

16.45 – 17.45 Company Presentations

17.45 – 19.15 Session II: Processes to find promising projects and future winners. What are today’s investment criteria?

Investors are facing hundreds of interest-ing projects and innovative ideas every year. Private investments in small and mid-sized companies hold great opportunities and risks at the same time. What are the key factors that make a project attractive for both inves-tors and the company? What are their reasons to invest in particular projects? How do inves-tors find these projects and which are their strategies?

20.00 – 22.30 Dinner

09.00 – 09.30 Registration / Breakfast

09.30 – 10.00 Keynote: Current partnering focus of big pharma

10.00 – 11.00 Company Presentations

11.00 – 11.30 Coffee Break

11.30 – 13.00 Session III: Compelling market opportunities for rare and ultra rare diseases. What are the financial, clinical and regulatory risks involved?

Drug pipelines are drying out and the number of blockbusters is declining. Orphan drugs seem to be one solution to that problem, because low sales volumes can be balanced out by premium prices. For small companies rare diseases offer the chance to develop drugs for niche markets with less competition. But do orphan drugs only offer benefits? Which are the risks that must be considered?

13.00 – 14.00 Lunch

14.00 – 15.30 Session IV: Chronic diseases – Are there novel therapies to improve the quality of life for individuals with chronic conditions?

Chronic diseases are a tough burden for patients and affect their whole life. Recurrent acute episodes complicate the treatment and present a particular challenge for medicine. What unmet medical needs are currently being addressed? How could the industry become a reliable partner in the daily life of patients with chronic diseases? Which conditions will be treated? Which medicines allow for an increase of the patient’s quality of life?

15.30 – 15.45 Closing remarks

15.45 Departure

Platinum Sponsor: Media Partner:

Register now: www.biodeutschland.org/registration-311.html

registration form 7th European Business Development Conference 23–24 September 2013 Dusseldorf, Germany(Register now! Space is limited to a maximum of 100 participants.)

delegate details (Please complete in capital letters)

First name ...................................................................................................................... Last name .............................................................................................................

Company ........................................................................................................................ Position .................................................................................................................

Address ...........................................................................................................................................................................................................................................................

City ........................................................................ Postal Code ................................................................ Country .................................................................................

Phone ............................................................................................................................. E-mail ...................................................................................................................

City, Date Company stamp, Signature

please fax this registration form to +49 30 72625-138 or register online: www.biodeutschland.org/registration-311.html

This exclusive workshop is organised for a limited number of participants with Small and Medium-sized Enterprises and international pharmaceutical companies in mind.

feesfor members of european, Special and regional partners+ Please mark your choice

Attendance € 545.00

Attendance and company presentation*

2nd delegate from same company**

€ 1,095.00

€ 390.00

+ ASEBIO, BIA, Bio.be, BIO Deutschland, BioFarmind, BIOTECanada, EAPB, EBE, Eucope, EuropaBio, LISA, Niaba, Norsk Biotekforum, SwedenBio and Swiss Biotech Association

for non-members of the associations mentioned above Please mark your choice

Attendance € 985.00

Attendance and company presentation*

2nd delegate from same company**

€ 1,975.00

€ 830.00

(VAT excluded (19 % VAT applicable). All bank charges to be paid by the forwarder.)

* Company presentation: Provided profiles of presenting companies will be included in delegate packages Presentation slots will be 15 minutes long (Q & A time included). Opportunities for additional discussion will be provided during one-to-one meetings, coffee breaks, lunch & dinner

** 2nd delegates are kindly requested to fill in a registration form as well

Terms and ConditionsCanCellaTIonNo reimbursement in case of cancellation after 1st September 2013.

replaCemenT deleGaTesIf you are unable to attend, you may transfer your registration to a colleague at no extra charge. Please confirm the details of the replacement in writing to events@biodeutschland.org (fax: +49-30-72625-138) before 10th September.

aCCommodaTIon (special rates only for booking before 23rd august)The conference fee does not include accommodation. Participants are invited to make their own arrangements. Rooms at the Hotel Meliã Dusseldorf are available at the price of € 89.00/140.00 per night w/o breakfast. Please use the keyword “EBDC-2013”.

THE VENUEHotel Meliã DusseldorfInselstraße 2, 40479 DüsseldorfTel. +49 211 522842121reservations.melia.duesseldorf@solmelia.comwww.melia-dusseldorf.com

paYmenTAn invoice will be mailed, upon receipt of your registration form. Fees should be remitted via bank transfer after receipt of the invoice, stating the invoice number, the name of the participant and the keyword “EBDC-2013”. Partici-pants will only be accepted at the conference on receipt of payment.

doCumenTaTIonParticipants will be provided with exclusive material.

amendmenTs To The proGramme / CanCellaTIon of The evenTIn the event of amendments being made to the conference agenda, they will be published on our website asap. However, we reserve the right to amend the programme content, timings or speakers without notice.In case of cancellation, our liability is limited to refund of registration fees only.

The Organiser shall not be liable for any failure or delay in performing any of its obligations if the failure or delay is due to any cause beyond its reasonable control, including unavailability of the venue of the Event, act of God, war, terrorist activity, civil commotion, malicious damage by a third party, strike, lock-out or other employee dispute, compliance with a law or governmental order, rule, regulation or directive, fire, flood or storm.

This contract is subject to German Law.